Effects of a Secondary Prevention Combination Therapy with beta-Blocker and Statin on Major Adverse Cardiovascular Events in Acute Coronary Syndrome Patients

18 August 2020: Clinical Research

Ling Zhu ^12ABCDEFG , Qianwei Cui ^1BCEF , Ying Liu ^3BCEF , Zhongwei Liu ^1BCE , Yong Zhang ^1BCF , Fuqiang Liu ^1ACDEFG* , Junkui Wang ^1ACDEFG*

DOI: 10.12659/MSM.925114

Med Sci Monit 2020; 26:e925114

Table 3 Multivariate Cox analysis of MACE in subgroups.

MACE	beta-Blocker monotherapy vs. Cotherapy*		Statin monotherapy vs. Cotherapy**
MACE	HR (95% CI)	P Value	HR (95% CI)	P Value
Model 1^a	0.39 (0.20–0.76)	.005	0.51 (0.28–0.92)	.025
Model 2^b	0.39 (0.20–0.77)	.006	0.50 (0.28–0.91)	.023
Model 3^c	0.37 (0.19–0.73)	.004	0.52 (0.29–0.95)	.034
Model 4^d	0.28 (0.13–0.59)	.001	0.54 (0.29–0.98)	.044
CI – confidence interval; HR – hazard ratio; MACE – major adverse cardiac event. ^* HR and values are based on comparison with beta-blocker monotherapy group; ^** HR and values are based on comparison with statin monotherapy group; ^a Model 1: Unadjusted; ^b Model 2: Multivariate adjustment was made for age, sex, smoking, body mass index; ^c Model 3: Multivariate adjustment was made for age, sex, smoking, body mass index, diabetes, hypertension, old myocardial infarction, atrial fibrillation; ^d Model 4: Multivariate adjustment was made for age, sex, smoking, body mass index, diabetes, hypertension, old myocardial infarction, atrial fibrillation, always use of aspirin, use of clopidogrel at 1 year, always use of angiotensin converting enzyme inhibitor or angiotensin receptor blocker, revascularization at baseline.